These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22024419)

  • 1. Ovulation induction with minimal dose of follitropin alfa: a case series study.
    Bruna-Catalán I; Menabrito M;
    Reprod Biol Endocrinol; 2011 Oct; 9():142. PubMed ID: 22024419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.
    Calaf Alsina J; Ruiz Balda JA; Romeu Sarrió A; Caballero Fernández V; Cano Trigo I; Gómez Parga JL; González Batres C; Rodríguez Escudero FJ
    BJOG; 2003 Dec; 110(12):1072-7. PubMed ID: 14664878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction.
    Serour GI; Aboulghar M; Al Bahar A; Hugues JN; Esmat K
    Reprod Biol Endocrinol; 2014 Jun; 12():52. PubMed ID: 24942155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study.
    Homburg R; Hendriks ML; König TE; Anderson RA; Balen AH; Brincat M; Child T; Davies M; D'Hooghe T; Martinez A; Rajkhowa M; Rueda-Saenz R; Hompes P; Lambalk CB
    Hum Reprod; 2012 Feb; 27(2):468-73. PubMed ID: 22128296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential low-dose step-up and step-down protocols with recombinant follicle-stimulating hormone in polycystic ovary syndrome: prospective comparison with step-down protocol.
    Casadei L; Puca F; Emidi E; Manicuti C; Madrigale A; Piccione E
    Arch Gynecol Obstet; 2012 Nov; 286(5):1291-7. PubMed ID: 22729136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different starting gonadotropin doses (50, 75 and 100 IU daily) for ovulation induction combined with intrauterine insemination.
    Streda R; Mardesic T; Sobotka V; Koryntova D; Hybnerova L; Jindra M
    Arch Gynecol Obstet; 2012 Oct; 286(4):1055-9. PubMed ID: 22736041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis.
    Martini AE; Beall S; Ball GD; Hayward B; D'Hooghe T; Mahony MC; Collares F; Catherino AB
    Front Endocrinol (Lausanne); 2023; 14():1195632. PubMed ID: 37727455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series.
    Yacoub S; Cadesky K; Casper RF
    J Ovarian Res; 2021 Feb; 14(1):31. PubMed ID: 33579321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa.
    Olivennes F; Trew G; Borini A; Broekmans F; Arriagada P; Warne DW; Howles CM
    Reprod Biomed Online; 2015 Mar; 30(3):248-57. PubMed ID: 25596910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa.
    Arce JC; Larsson P; García-Velasco JA
    Reprod Biomed Online; 2020 Oct; 41(4):616-622. PubMed ID: 32819842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain.
    Burgués S;
    Hum Reprod; 2001 Dec; 16(12):2525-32. PubMed ID: 11726569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
    Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
    Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
    Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
    Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.
    Fernández-Sánchez M; Visnova H; Yuzpe A; Klein BM; Mannaerts B; Arce JC;
    Reprod Biomed Online; 2019 Apr; 38(4):528-537. PubMed ID: 30713022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
    Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
    Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.
    Saz-Parkinson Z; López-Cuadrado T; Bouza C; Amate JM
    BioDrugs; 2009; 23(1):37-42. PubMed ID: 19344190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
    Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
    Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovulation induction and controlled ovarian stimulation using letrozole gonadotropin combination: A single center retrospective cohort study.
    Arya S; Kupesic-Plavsic S; Mulla ZD; Dwivedi AK; Crisp Z; Jose J; Noble LS
    Eur J Obstet Gynecol Reprod Biol; 2017 Nov; 218():123-128. PubMed ID: 28985546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.